Skip to main content
. 2021 Aug 2;54(2):434–444. doi: 10.4143/crt.2021.671

Table 3.

The selective adverse events of EGFR-TKIs plus bevacizumab (n=36)

Adverse event Any grade Grade ≥ 3
Skin rash/Acne 30 (83.3) 3 (8.3)
Diarrhea 16 (44.4) 0
Paronychia 16 (44.4) 0
Proteinuria 15 (38.9) 1 (2.8)
Stomatitis 13 (36.1) 1 (2.8)
Increased aminotransferase 11 (30.6) 3 (8.3)
Hypertension 5 (13.9) 0
Bleeding 4 (11.1) 0

Values are presented as number (%). EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.